Deutsche Bank AG Acquires 115,672 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Deutsche Bank AG increased its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 196.0% in the fourth quarter, HoldingsChannel reports. The firm owned 174,702 shares of the company’s stock after buying an additional 115,672 shares during the period. Deutsche Bank AG’s holdings in Lineage Cell Therapeutics were worth $87,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Alyeska Investment Group L.P. acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter valued at $1,984,000. Renaissance Technologies LLC grew its stake in shares of Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after acquiring an additional 2,085,972 shares in the last quarter. DAFNA Capital Management LLC grew its stake in shares of Lineage Cell Therapeutics by 85.9% in the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company’s stock valued at $1,262,000 after acquiring an additional 1,160,666 shares in the last quarter. Raffles Associates LP grew its stake in shares of Lineage Cell Therapeutics by 21.8% in the fourth quarter. Raffles Associates LP now owns 5,492,088 shares of the company’s stock valued at $2,760,000 after acquiring an additional 984,307 shares in the last quarter. Finally, Comerica Bank lifted its position in Lineage Cell Therapeutics by 220.0% during the fourth quarter. Comerica Bank now owns 800,000 shares of the company’s stock worth $402,000 after purchasing an additional 550,000 shares during the period. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Price Performance

Lineage Cell Therapeutics stock opened at $0.68 on Wednesday. The business has a 50 day moving average of $0.49 and a 200-day moving average of $0.62. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.37 and a 1 year high of $1.15. The company has a market capitalization of $149.44 million, a P/E ratio of -5.65 and a beta of 1.21.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. B. Riley cut their price objective on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 14th. D. Boral Capital reissued a “buy” rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $4.20.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.